BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250422
DTEND;VALUE=DATE:20250425
DTSTAMP:20260515T052246
CREATED:20241128T082522Z
LAST-MODIFIED:20241128T082522Z
UID:40196-1745280000-1745539199@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences West
DESCRIPTION:LEAP HR: Life Sciences West is your chance to explore how leading and emerging biopharma organizations are navigating industry volatility and preparing for the workforce of tomorrow. As the sector recovers from funding challenges and workforce reductions\, discover innovative ways to align your HR strategy with evolving business needs in 2025 and beyond. \nJoin 200+ HR leaders to uncover how the most agile organizations are reshaping total rewards strategies to gain a competitive edge in a fiercely competitive talent market. Learn how they’re redefining employee engagement to boost retention and creating flexible workforce planning strategies to adapt to rapid industry changes. \nThis is your opportunity to rethink HR practices and position your organization for long-term success in Life Sciences. \nTo know more visit: https://ter.li/fxwk88
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-west/
LOCATION:Grand Hyatt San Francisco\, 345 Stockton St\, San Francisco\, CA\, 94108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250409
DTEND;VALUE=DATE:20250411
DTSTAMP:20260515T052246
CREATED:20250228T122457Z
LAST-MODIFIED:20250228T122457Z
UID:40603-1744156800-1744329599@www.pharmajournalist.com
SUMMARY:Tumour Models Summit Nordics
DESCRIPTION:Welcome to the first ever Tumour Models Summit Nordics. This April\, the critically acclaimed Tumour Models series will be coming to the Nordics for the first time ever\, uniting more than seventy pharma\, biotech\, and research leaders across the Nordic biotech landscape. \nThe inherent heterogeneity of cancer – both inter-patient and intra-tumoral – remains a significant challenge in cancer modelling. With only 5% of cancer drugs successfully advancing to clinical trials\, there is a critical need for more accurate and predictive models to guide therapeutic development. \nTo serve this need\, the Tumour Models Summit Nordics will unite pharma\, biotech\, and research leaders from across the thriving Nordic biotech ecosystem to tackle this challenge head-on for the first time ever. Experts working across preclinical\, translational\, discovery\, toxicity\, and biology will gather in Stockholm this April to collaborate and overcome the industry’s biggest obstacles for 2025. As the region’s only industry-led event of its kind\, this summit provides a rare opportunity to connect with top experts from these developmental areas. \nGain insights into the cutting-edge innovation in in vivo and in vitro tumour modelling\, discover strategies to de-risk your studies\, and learn how to refine your drug development pipeline. \nKey highlights of the agenda include: \n\nLeveraging cutting-edge 3D in vitro models with Roche\nTarget/receptor axis modelling with Anocca\nHumanised mouse models with BioInvent\nAdvanced omics data with Curacell\nTreating solid tumours with Hemispherian\n\nPrevious attendees of the Tumour Models Summits in Boston\, San Francisco\, and London have celebrated the summit’s range\, relevance\, and focus with comments such as\, “This summit included the most cutting-edge achievements and potential collaborations in the scientific and industrial world” (Roche)\, and “The conference exceeded my expectations. The talks were very relevant to my day-to-day work as in vivo scientist in a cell therapy company. I enjoyed the networking; attendees were very approachable” (Arsenal Biosciences). \nFind out why they said this and secure your free pass to join us to engage with decision-makers\, explore groundbreaking solutions\, and accelerate the path from lab to patient in today’s rapidly evolving landscape. \nWe’ll see you there! \nGet your free pass now whilst still available: https://ter.li/qdc9zo
URL:https://www.pharmajournalist.com/event/tumour-models-summit-nordics/
LOCATION:Hilton Stockholm Slussen\, Guldgränd 8\, Stockholm\, 104 65\, Sweden
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250408
DTEND;VALUE=DATE:20250411
DTSTAMP:20260515T052246
CREATED:20250214T121248Z
LAST-MODIFIED:20250214T121248Z
UID:40497-1744070400-1744329599@www.pharmajournalist.com
SUMMARY:15th World Clinical Biomarkers & Companion Diagnostics Summit Europe
DESCRIPTION:As recent advances in small molecules\, ADCs\, cell\, and gene therapies poise novel precision therapies from the bench to the clinic\, the 15th World Clinical Biomarkers & Companion Diagnostics Summit Europe returns as the industry-leading end-to-end forum for Europe’s precision medicine community. \nOver three days\, 170+ key stakeholders from across Europe working in Biomarkers\, Translational Medicine\, Precision Medicine\, and Companion Diagnostics will come together to: \n\nBolster biomarker discovery and validation\nImplement novel technologies and trials\nPioneer digital and AI-enabled innovations\nOptimise drug-diagnostic co-development\nStreamline CDx development and commercialisation\nNavigate IVDR-adherence\n\nWhen? 8th-10th April\, 2025 \nWhere? London\, UK \nSee the brochure: https://ter.li/exx85v \nWith free* tickets available for biopharma\, check our T&Cs\, or view our early bird savings and group discounts: https://ter.li/5uhfl8
URL:https://www.pharmajournalist.com/event/15th-world-clinical-biomarkers-companion-diagnostics-summit-europe/
LOCATION:London\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250401
DTEND;VALUE=DATE:20250404
DTSTAMP:20260515T052246
CREATED:20250127T201431Z
LAST-MODIFIED:20250127T201431Z
UID:40370-1743465600-1743724799@www.pharmajournalist.com
SUMMARY:6th TCR-Based Therapies Summit
DESCRIPTION:Returning as the only event created selectively for and by the TCR community\, the 6th TCR-based Therapies Summit (April 1-3\, 2025 | Boston\, MA) is your unique opportunity to connect and collaborate with TCR developers and experts to battle the specific discovery\, preclinical and clinical challenges created by T cell receptor biology to advance cell- and bispecific approaches. \nView the 25+ experts speaking in 2025 including Adaptimmune\, Immunocore\, Immatics\, BioNTech\, T-Knife\, TScan\, and Affini-T Therapeutics. \nView the full lineup of presenting companies in the 2025 Event Guide. \nReturning as a much-loved forum by industry leaders in this close-knit community\, I’m sure you want to know what’s new for the 2025 meeting: \n\nPlethora of new data: Over 60% of talks will share new data\, including clinical insights and advances\, novel target case studies\, and innovations utilizing AI\, machine learning\, engineering methods\, and cell tracking\nBreadth of TCR Approaches: Uncover the realm of TCR targeting methods including TCR-Ts\, TCR-NKs\, bispecifics\, T-cell engagers\, TCR-like antibodies\, and mimics\, and distinguishing the optimal approach for different indications\n7 New Companies & 85% New Speakers: Unlock innovations from companies such as Moonlight Bio\, Synteny\, Alkemist Bio\, Pan Cancer T\, and Aethon Therapeutics making their TCR-Based Therapies Summit debut and hear new perspectives from a highly refreshed speaker faculty\nApplications Beyond Oncology: Discover how TCR therapies can be utilized to treat novel indications\, such as autoimmunity and infectious diseases\, and harness cross-learnings to propel your therapeutic development\n\nView the full program. \nFollowing Adaptimmune’s milestone approval\, the 2025 meeting is anticipated to be one of the best yet. With so much to celebrate\, momentum to capture\, novel insights\, and collaboration with like-minded experts at the only TCR-specific event. \nQuick links: Website | Event Guide | Register
URL:https://www.pharmajournalist.com/event/6th-tcr-based-therapies-summit/
LOCATION:The Revere Hotel Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250401
DTEND;VALUE=DATE:20250404
DTSTAMP:20260515T052246
CREATED:20241204T190232Z
LAST-MODIFIED:20241204T190232Z
UID:40220-1743465600-1743724799@www.pharmajournalist.com
SUMMARY:2nd Peptide-Based Therapeutics Summit
DESCRIPTION:The 2nd Peptide-Based Therapeutics Summit will return to Boston in April 2025\, bringing together over 80 experts in peptide computational science\, medicinal chemistry\, and formulation to discuss the latest advancements shaping the next generation of peptide-based therapies—from early-stage discovery to clinical application. \nDownload the three-day program here: https://ter.li/rrvg1v \nThis year’s summit will highlight groundbreaking innovations in peptide therapeutics\, including: \n\nPeptide 3D structure prediction\, hit generation\, and lead optimization\, featuring insights from Chugai Pharmaceutical\, PeptiDream\, and Insamo\nStrategies for optimizing oral bioavailability and cell permeability in peptide design\, with contributions from Orbis Medicines and Ohio State University\nPeptide formulation techniques for optimal target binding\, solubility\, stability\, and safety\, with expertise from Halozyme and Oramed Pharmaceuticals\n\nJoin us to shape your peptide drug discovery and development strategy for 2025 and discover the therapeutic potential of cutting-edge peptide-based medicines.
URL:https://www.pharmajournalist.com/event/2nd-peptide-based-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250401
DTEND;VALUE=DATE:20250404
DTSTAMP:20260515T052246
CREATED:20241127T123831Z
LAST-MODIFIED:20241127T123902Z
UID:40151-1743465600-1743724799@www.pharmajournalist.com
SUMMARY:Nasal Formulation & Delivery Summit
DESCRIPTION:With nasal delivery systems offering faster absorption and non-invasive administration\, they are becoming a cornerstone of modern therapeutics. Whether for nose-to-brain delivery or emergency use\, nasal delivery is opening a new era of more efficient drug and vaccine administration with life-saving potential. However\, challenges in biologics formulation\, along with renewed interest from major pharmaceutical companies and investors\, raise questions about how other companies are addressing development obstacles and the most effective strategies to secure funding. \nDedicated to navigating investment pathways for nasal companies\, boosting drug bioavailability in target regions\, optimizing translational modelling\, and determining the efficacy of delivery devices\, the 3rd Nasal Formulation & Delivery Summit will unite biotechs and innovative start-ups to share case studies and best practices in optimizing nasal drug delivery across different therapeutic areas. \nDownload the event guide for full details: https://ter.li/qd1z5z \nEarly bird savings and group discounts up to 20% are available\, check out the options here: https://ter.li/u7ehtp
URL:https://www.pharmajournalist.com/event/nasal-formulation-delivery-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250326
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T052246
CREATED:20250206T124811Z
LAST-MODIFIED:20250206T124811Z
UID:40435-1742947200-1743119999@www.pharmajournalist.com
SUMMARY:2nd DNA Process Development & Manufacturing Summit
DESCRIPTION:The 2nd DNA Process Development & Manufacturing Summit: Accelerating Innovative Advanced Therapies with Revolutionary Plasmid & Enzymatic DNA. \nWith the plasmid DNA manufacturing market set to rise to $39.3Bn by 2033\, and the demand for advanced therapies continuing to surge as gene therapy reaches new heights and DNA vaccines promise to transform outbreak response\, there has never been a more crucial time to revolutionize the production of high-quality DNA as a starting material and API. \nThe 2nd DNA Process Development & Manufacturing Summit 2025 returns as the world’s only industry-dedicated technical forum focused on optimizing process development for plasmid and cell-free DNA\, adhering to regulatory requirements to streamline IND approvals for advanced therapies\, and developing scalable\, efficient manufacturing solutions.\nIndustry experts from the likes of Pfizer\, Sanofi\, Novartis\, Beam Therapeutics\, Moderna\, Merck and Chroma Medicine are uniting to share innovations in plasmid design\, advances off-the-shelf lysis equipment and purification techniques\, and strategies to support timely\, cost-efficient large-scale DNA production. \nFind out more: https://ter.li/7k68s7
URL:https://www.pharmajournalist.com/event/2nd-dna-process-development-manufacturing-summit/
LOCATION:The Hyatt Regency\, 1 Ave de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T052246
CREATED:20250123T121746Z
LAST-MODIFIED:20250123T121746Z
UID:40347-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:7th Treg-Directed Therapies Summit
DESCRIPTION:Over the past year\, the Treg sector has seen groundbreaking investments and strategic collaborations between leading biotech and pharma companies like Quell and AstraZeneca\, and Parvus and AbbVie\, creating a surge of innovation and spotlighting Treg cell therapies and modulators as the next frontier in autoimmune and inflammatory disease treatments. Tregs hold the potential to revolutionize care for conditions that have long lacked effective solutions and are the future of precision medicine in autoimmune and inflammatory diseases. \n \nThe 7th Treg-Directed Therapies Summit is your premier event dedicated to exploring and overcoming the unique challenges and advancements specific to Treg. Offering you exclusive access to the latest industry insights\, clinical data\, Treg biology breakthroughs and strategies for advancing therapies to the clinic from trailblazing companies and academic leaders\, including Abata Therapeutics\, Harvard Medical School\, Nektar Therapeutics\, Parvus Therapeutics\, PolTreg\, ThyTech and many more! \nWhether you are in discovery\, navigating the complexities of IND filings\, or transitioning to the clinic\, this forum provides an unparalleled opportunity to engage with leaders at the forefront of cell therapy and modulator innovation. Connect with senior experts in cell therapy manufacturing and modulator production\, build strategic relationships with investors\, pharmaceutical companies and academics\, opening doors to future collaborations and partnership opportunities. \nEvent guide link: https://ter.li/adqtg1
URL:https://www.pharmajournalist.com/event/7th-treg-directed-therapies-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T052246
CREATED:20250116T124349Z
LAST-MODIFIED:20250116T124349Z
UID:40335-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:2nd EHS for Biopharma Summit East
DESCRIPTION:As the biopharma industry evolves with rapid advancements in drug development\, manufacturing\, and research\, EHS leaders are tasked with safeguarding employee health\, maintaining a culture of safety\, and addressing environmental concerns. Navigating these challenges while meeting sustainability goals and mitigating risks has become essential for operational success. EHS professionals must continuously adapt to this dynamic landscape to protect their most valuable asset: their workforce. \nThe 2nd EHS for Biopharma East Summit is an essential event for EHS professionals working in the biopharma industry\, focused on overcoming the sector’s unique regulatory and operational challenges. With over 100+ attendees\, this summit will provide valuable insights on navigating evolving regulations\, optimizing safety protocols\, and enhancing environmental stewardship. Whether your goal is to strengthen safety culture\, reduce incidents\, or achieve sustainability targets\, the summit offers the tools\, knowledge\, and networking opportunities necessary to elevate EHS practices. \nWhat can you expect? – Your Definitive Guide to EHS for Biopharma \n\nDiscover actionable strategies for managing global EHS challenges with insights from Astellas\, MilliporeSigma\, and Elanco\nEnhance safety culture in laboratory and manufacturing settings with guidance from AstraZeneca\, Texcell\, and Cytovance\nLearn best practices for embedding EHS programs within the workforce\, fostering leadership buy-in\, employee engagement\, and promoting psychological well-being to minimize burnout\nExplore the latest technologies driving EHS excellence with expertise from AstraZeneca and Sanofi\nConnect with industry peers to network and benchmark best practices.\nEarn continuing education credits from BCSP\, ABSA\, and CIH\n\nCreated for EHS professionals spanning EHS directors\, EHS managers and EHS technical experts focused on workplace safety\, environmental compliance\, and operational excellence. \nJoin us this March \nFind out more here \nRegister your place
URL:https://www.pharmajournalist.com/event/2nd-ehs-for-biopharma-summit-east/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T052246
CREATED:20241212T121823Z
LAST-MODIFIED:20241212T121823Z
UID:40241-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:2nd Biophysics for Drug Discovery Summit
DESCRIPTION:In today’s complex drug development landscape\, leveraging biophysical tools to unravel the molecular and target engagement intricacies of drug candidates is more critical than ever for successfully advancing molecules through the drug development pipeline. The 2nd Biophysics for Drug Discovery Summit is your exclusive opportunity to unite and network with your biophysics and drug discovery peers and delve into the application of biophysical techniques including SPR\, NMR\, Thermal shift assays\, mass spec\, and the emerging technologies\, across modalities and targets to inform efficient drug discovery. \n \nThe Biophysics for Drug Discovery Summit will delve into the latest in strategy and application of biophysical techniques across novel targets and modalities\, from AI-driven drug discovery to fragment-based drug discovery\, and in-cell biophysics to single-particle tracking. By understanding the intricate molecular mechanisms and improving hit selection and target identification\, we can accelerate the discovery of innovative therapies and improve the effectiveness and efficiency of drug development. \nUnlock the future of therapeutics through biophysics and keep up to date as field evolves into new technologies and applications\, this meeting will provide you with thought-provoking insights on biophysics applications to take away to your wider drug discovery teams. Join the Biophysics for Drug Discovery Summit in March 2025 and build meaningful connections with 70+ biophysicists and drug discovery experts and move the field forward with unique insights and deep-dive conversations. \nTo know more visit: https://ter.li/8u0s3n
URL:https://www.pharmajournalist.com/event/2nd-biophysics-for-drug-discovery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T052246
CREATED:20241127T125100Z
LAST-MODIFIED:20241127T125100Z
UID:40163-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:8th Gene Therapy Development Summit
DESCRIPTION:With 14 new gene therapy approvals in the last 18 months\, billion-dollar collaborations\, and the development of treatments for more common conditions\, the gene therapy field is rapidly gaining momentum and broadening scope beyond rare diseases. \nReturning to Boston in March\, the 8th Gene Therapy Development Summit\, formerly known as the Gene Therapy for Rare Disorders Summit\, will unite 200+ gene therapy experts to tackle the field’s biggest challenges of achieving genuine scalability and accessibility to meet growing patient demand. \nFor the first time\, this industry-defining meeting will reflect the field’s growing focus on developing therapies for common diseases\, whilst addressing existing hurdles in rare and ultra-rare disorders. This is your unparalleled opportunity to delve into: \n\nThe latest global regulatory requirements\nOptimizing routes for CNS\nOcular and inner ear disorders\nInnovations in capsid engineering and dosing strategies\nIncreasing volumetric productivity to reduce CoGs\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:https://www.pharmajournalist.com/event/8th-gene-therapy-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T052246
CREATED:20241127T122738Z
LAST-MODIFIED:20241127T122738Z
UID:40140-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:4th Novel Conjugate Summit
DESCRIPTION:The field of conjugatable drugs is advancing at a rapid pace\, with major collaborations like Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals\, which paves the way towards a new generation of more targeted\, safer and efficacious novel conjugated drugs. \nThe 4th Novel Conjugates Summit is the only event offering comprehensive insights into the latest innovations in bioconjugates. From antibody-degrader conjugates to bispecific ADCs and peptide drug conjugates\, join us to delve into each of their value propositions and navigate crucial considerations like target selection\, PK/PD profiles\, and translation into the clinic. \nConnect with 100+ experts from big pharma\, cutting-edge biotechs and conjugation and manufacturing providers\, all sharing crucial insights on striking success with new formats and payloads. \nNow is the time to expand your conjugate design toolkit to pursue emerging cancer targets and stay ahead in the race to deliver safer\, more targeted therapies beyond traditional ADCs Join us to explore the most promising new targeting vectors and payloads that are set to revolutionize the landscape of conjugated drugs in 2025!
URL:https://www.pharmajournalist.com/event/4th-novel-conjugate-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250318
DTEND;VALUE=DATE:20250321
DTSTAMP:20260515T052246
CREATED:20250127T202012Z
LAST-MODIFIED:20250127T202012Z
UID:40377-1742256000-1742515199@www.pharmajournalist.com
SUMMARY:5th Wet AMD Diabetic Eye Disease Drug Summit
DESCRIPTION:With Merck’s acquisition of EyeBio for $1.3 Billion\, Roche’s Vabysmo launch success and multiple other phase II and III trials in DME\, DR\, RVO\, and Wet AMD\, there is plenty to discuss in the retinal vascular drug space as drug developers seek to new alternatives to anti-VEGF\, explore biosimilars\, and target retinal fibrosis and more to find truly transformative drugs for patients. \n \nThe 2025 Wet AMD & Diabetic Eye Disease Summit is set to be an essential meeting for industry leaders\, research innovators\, and clinical experts dedicated to transforming the landscape of retinal vascular disease treatments. \nWhat’s New for the 2025 Wet AMD & Diabetic Eye Disease Drug Summit? \n\nNew Strategies for Retinal Vascular Drug Clinical Trials: Delve into advanced strategies for designing clinical trials in Wet AMD and diabetic eye disease\, focusing on patient-specific factors and adaptive trial models with insights from Bayer and Aviceda Therapeutics\nEmerging Biomarker Approaches Wet AMD\, DR. DME & RVO: Explore the critical role of biomarkers and clinical endpoints in developing therapies for neovascular retinal disorders\, featuring discussions from Opus Genetics and Ocugen\nInnovative Oral Anti-Inflammatory Treatments for Diabetic Eye Disease: Discover how InflammX Therapeutics is addressing the unmet need in DR and DME patients non-responsive to anti-VEGF therapy with their once-daily oral small molecule\nAdvancements in Retinal Drug Delivery: Discover the benefits of suprachoroidal TKI delivery for Wet AMD with Clearside Biomedical\, and hear from Sanofi about incorporating drug delivery devices to improve physician efficiency and patient compliance\nBreakthroughs in Wet AMD Gene Therapy: Learn about emerging gene therapies for Wet AMD\, focusing on innovative approaches and potential impact on patient care with HuidaGene Therapeutics Doheny Eye Centers\n\nJoin 50+ biopharma experts from clinical\, medical\, regulatory. value and access departments from Bayer\, Sanofi\, EyePoint\, Ocular Therapeutix\, Clearside Biomedical\, RevOpsis\, Opus Genetics\, and HuidaGene Therapeutics as they accelerate towards releasing longer-lasting\, non-invasive and more effective drugs for retinal disease patients. \nTo know more visit: https://ter.li/sew767
URL:https://www.pharmajournalist.com/event/5th-wet-amd-diabetic-eye-disease-drug-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250318
DTEND;VALUE=DATE:20250321
DTSTAMP:20260515T052246
CREATED:20241107T144640Z
LAST-MODIFIED:20241107T144640Z
UID:40031-1742256000-1742515199@www.pharmajournalist.com
SUMMARY:The 5th Operationalize: Expanded Access Programs Summit
DESCRIPTION:Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. However\, challenges persist\, especially when navigating the complex regulatory landscape of global programs. From country-specific regulations to post-trial access\, managing global supply chains\, importation\, licensing\, and labeling standards remains a critical focus for ensuring patients worldwide receive the treatments they need. \nJoin over 120 thought leaders from Access\, Medical Affairs\, Clinical Operations\, and Clinical Supply for an unparalleled opportunity to network\, exchange insights\, and explore innovative strategies for overcoming the regulatory and operational hurdles that complicate global access to life-saving therapies. \nAt this year’s summit\, you’ll gain actionable insights on successfully planning and executing Post-Trial Access Programs\, navigating the regulatory landscapes of the US\, LATAM\, Europe\, and South & East Asia\, and developing compliant\, effective global access strategies. You’ll also explore best practices for creating exit plans and transition strategies that address hurdles in reimbursement\, off-request processes\, and country-specific regulations—plus so much more! \nTo know more visit: https://ter.li/org1vd
URL:https://www.pharmajournalist.com/event/the-5th-operationalize-expanded-access-programs-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250311
DTEND;VALUE=DATE:20250314
DTSTAMP:20260515T052246
CREATED:20250211T125459Z
LAST-MODIFIED:20250211T125459Z
UID:40474-1741651200-1741910399@www.pharmajournalist.com
SUMMARY:6th Supply Chain & Logistics for Cell & Gene Therapies Summit
DESCRIPTION:The 6th Supply Chain & Logistics for Cell & Gene Therapies Summit is the ultimate practical guide for designing scalable\, traceable\, and resilient global supply chains to support the growing number of complex cell and gene therapies. It is an industry wide challenge and vital part of development\, to ensure safe and timely delivery to patients. This relies on robust global supply chains. \nThe 2025 summit will provide a comprehensive deep dive into end-to-end global supply chains for cell and gene therapies\, covering autologous\, allogeneic\, in vivo\, and ex vivo programs. This is the industry’s premier platform to hear from more than 20 leading voices spanning clinical and commercial drug developers\, trusted service providers\, and clinical experts who will be sharing solution-driven case studies. These will focus on key areas such as defining robust processes\, securing reliable material supplies\, implementing digital solutions\, and ensuring seamless traceability of chain of identity and custody throughout the cold chain. \nOur 90+ attendees will gain invaluable and actionable insights on how to become commercial-ready\, expand globally\, and enhance cross-functional collaboration. The summit will unite professionals from Supply Chain\, Logistics\, Sourcing\, Quality\, and Operations sectors\, who will share best practices in supply planning\, manufacturing\, packaging\, labeling\, and delivery. Together\, they will brainstorm practical solutions for an integrated approach that strengthens value chains. \nFor those planning or executing a scaled\, integrated CGT supply chain\, this summit provides a unique opportunity to innovate and address the logistical and operational challenges currently facing the industry. As the industry’s premier networking and knowledge-based event dedicated to optimizing cell and gene therapy supply chains\, you don’t miss out on this opportunity to network\, learn\, and collaborate with experts in the field. \nTo learn more about who will be attending including those from Novartis\, Beam Therapeutics\, Astellas Gene Therapies\, and more – download the event guide now. \nTo know more visit: https://ter.li/yjybt6
URL:https://www.pharmajournalist.com/event/6th-supply-chain-logistics-for-cell-gene-therapies-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250311
DTEND;VALUE=DATE:20250314
DTSTAMP:20260515T052246
CREATED:20241111T113610Z
LAST-MODIFIED:20241114T113531Z
UID:40065-1741651200-1741910399@www.pharmajournalist.com
SUMMARY:4th Cell Therapy Potency Assay Summit
DESCRIPTION:In the current cell therapy landscape\, where funding is tight and clinical development a priority\, developing robust potency assays is critical to avoid costly delays. Introducing the 4th Cell Therapy Potency Assay Summit\, uniting AD\, QC and regulatory experts\, this summit works to design potency assays that not only conform to changing guidelines but also streamline patient access to the next generation of cell therapies. \nJoin leading organizations like Arsenal Biosciences\, BlueRock Therapeutics\, the NIST and Vertex Pharmaceuticals\, as they share development strategies and the latest technologies needed to streamline your assay development workflows. You won’t want to miss out! \nTo know more visit: https://ter.li/inqax5
URL:https://www.pharmajournalist.com/event/4th-cell-therapy-potency-assay-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250303
DTEND;VALUE=DATE:20250307
DTSTAMP:20260515T052246
CREATED:20241128T113542Z
LAST-MODIFIED:20241128T113542Z
UID:40201-1740960000-1741305599@www.pharmajournalist.com
SUMMARY:15th World ADC London Summit 2025
DESCRIPTION:Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval\, the field has seen a surge in multi-billion-dollar acquisitions\, commercialisation deals\, and licensing agreements. These developments have enabled the ADC community to make strides in bringing these therapies to earlier-line treatments and expand their use to wider patient populations. \nReturning for its 15th anniversary year\, World ADC London is the leading European conference uniting over 1000 ADC enthusiasts to maximise the therapeutic index of ADCs. Whether you are brand new to the field or have over a decade of experience\, work in discovery or manufacturing\, hold a strategic position or work day-to-day in the lab\, this meeting offers something for you! \nTake a look at the full agenda here. \nEmbark on a knowledge-rich adventure as we explore the intricate nuances of ADC development. From the initial stages of target identification and antibody engineering to the complexities of clinical trials and CMC strategies to navigating commercialisation\, expect to leave this event with a comprehensive understanding of the entire ADC lifecycle. \nHere are some of the leading minds sharing translatable lessons to advance your pipeline including: \n\nAlireza Tafazzol\, Senior Scientist II\, Oncology Bioinformatics\, AbbVie.\nOsama Chahrour\, Principal Scientist\, Chemical Development\, AstraZeneca.\nYu-Shin Hsu\, Research Analyst\, Independent.\nJinwon Jung\, Senior Director\, Protein Engineering\, ABL Bio.\nHayley Jackman\, Director\, CMC Regulatory Affairs\, AstraZeneca.\nLolke de Haan\, Vice President\, Toxicology\, ADC Therapeutics.\nMax Lee\, Associate Director\, AstraZeneca.\nPaul WolstenholmeHogg\, Vice President\, Medicinal Chemistry\, ADC Therapeutics.\nTomohiro Fujii\, ADC Researcher\, Ajinomoto Bio-Pharma Services.\nYing Buechler\, Chief Technology Officer\, Ambrx\, a Johnson & Johnson Company.\nPaul Jaminet\, Chief Executive Officer\, Angiex.\nUchechukwu OkorjiObike\, Senior Scientist\, Bioassay Development\, AstraZeneca.\n\nSee the full speaker faculty and session details here. \nDon’t miss this chance to unlock unmissable R&D\, focused industry networking opportunities\, and emerging trends taking hold of the ADC field with sessions from 120+ world-leading speakers including Daiichi Sankyo\, AstraZeneca\, Pfizer\, AbbVie\, Merck\, GSK\, Johnson & Johnson\, ADC Therapeutics and more.
URL:https://www.pharmajournalist.com/event/15th-world-adc-london-summit-2025/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250303
DTEND;VALUE=DATE:20250306
DTSTAMP:20260515T052246
CREATED:20241008T141820Z
LAST-MODIFIED:20241008T141820Z
UID:39880-1740960000-1741219199@www.pharmajournalist.com
SUMMARY:10th Annual Innate Killer Summit
DESCRIPTION:2025 is shaping up to be the ‘bounce back’ year for natural killer therapy. For the first time we are seeing efficacious in-patient data\, expansion into autoimmune disease\, and combination approaches all take off! So\, we are proud to announce the 10th Anniversary Innate Killer Summit returning to San Diego this March\, to showcase all the above and much more. \nCarefully compiled alongside industry experts from Artiva Biotherapeutics\, Immunity Bio\, INmune Bio and UCL (just to name a few!)\, our agenda will provide you with the latest clinical data in NK cells\, engagers\, cytokines and more\, to revolutionize and accelerate innate therapies once again. \nAnd that’s not all! Owing to the overwhelming excitement\, in 2025 we will introduce a *BRAND-NEW* Applications of NK Biology to Autoimmunity Focus Day\, alongside critical workshops exploring cryopreservation and donor selection\, to provide your company with the NK insights needed to pave your future in innate immunity treatment. \nSecure your place to join us in celebrating a decade of uniting longstanding pioneers and trailblazers in the NK space! \nTo know more visit: https://ter.li/fqxr57
URL:https://www.pharmajournalist.com/event/10th-annual-innate-killer-summit/
LOCATION:DoubleTree by Hilton – San Diego Mission Valley\, 7450 Hazard Center Drive\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T052246
CREATED:20241204T185205Z
LAST-MODIFIED:20241204T185205Z
UID:40215-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:TRP Target Selection & Drug Design Summit
DESCRIPTION:The radiopharmaceutical race is on and pharma leaders such as AstraZenca\, BMS \, Eli Lilly\, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical Mariana Oncology\, Radionetics and Aktis Oncology\, the field is turning to cutting-edge\, novel targeting molecules and new targets to address more unmet medical need. With strong clinical efficacy from blockbuster drugs Pluvicto and Lutathera\, radiopharmaceutical leaders are looking for the next application of this highly efficacious and potent modality! \nThe inaugural Targeted Radiopharmaceuticals Target Selection & Drug Design Summit is your dedicated forum to advancing novel radiopharmaceutical drug discovery. Delve deep into target mining\, screening\, discovery and selection from ROR1\, uPAR\, B7-H3\, NECTIN-4\, CAIX and more. Understand advances in radiobiological\, radiodecay and radiation absorption mechanisms to inform optimal targeting strategies from small molecule\, peptide\, nanobodies\, antibody fragments as well as linker and chelator technologies for enhanced PK. Bringing it all together\, gain a commercial perspective to enhance your strategic decision-making in target selection and novel drug rationale within this highly dynamic field. \nIncorporating key insights from radiopharmaceuticals’ leading drug discovery minds from medicinal chemistry\, radiobiology\, biology\, discovery\, R&D\, pharmacology\, computational biology\, commercial strategy and many more\, this is the only global opportunity to gain practical insights into your approaches\, from target selection to drug design. \nUniting the discovery experts pioneering the field\, join the inaugural TRP Target Selection & Drug Design Summit to understand exactly what targets match the strong therapeutic index of TRPs and uncover optimal targeting strategies for stellar drug discovery! \nTo know more visit: https://ter.li/95a3xm
URL:https://www.pharmajournalist.com/event/trp-target-selection-drug-design-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T052246
CREATED:20241031T112011Z
LAST-MODIFIED:20241031T112011Z
UID:39992-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:4th mRNA Analytical Development & Quality Control Summit
DESCRIPTION:4th mRNA Analytical Development & Quality Control Summit | February 25-27\, 2025 \nExcitement for mRNA therapeutics continues\, as RNA technologies are awarded the Nobel Prize for the second year running. Yet\, despite optimized analytics\, critical quality control methodology and robust assay development leading to efficient approvals and commercialization\, knowledge gaps persist in phase-appropriate assays\, analyzing LNP payloads and novel cell-targeted delivery systems\, and controlling dsRNA. Not to mention the challenges posed by regulations! \nWith exclusive FDA insight\, the 4th mRNA Analytical Development & Quality Control Summit returns; uniting the Analytical\, Quality\, and Assay Development teams at one central forum for the first time to finally address shared challenges and cross-department priorities to ensure successful regulatory submissions. \n\nDates: February 25-27\, 2025\nLocation: Revere Hotel Boston Common\, Boston\, Massachusetts\nEvent Program: https://ter.li/h10rnn\n\nBringing together 100+ Scientists\, Directors and Heads of Analytical Development\, Quality Control\, Assay Development\, CMC and Regulatory Affairs\, join your peers to take part in critical conversations and ensure the identity\, safety and efficacy of your RNA medicines. \nDownload the agenda here: https://ter.li/h10rnn \nView your registration options\, early bird savings\, and group discounts: https://ter.li/ku4oky \n 
URL:https://www.pharmajournalist.com/event/4th-mrna-analytical-development-quality-control-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T052246
CREATED:20241029T113934Z
LAST-MODIFIED:20241029T113934Z
UID:39973-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:8th CAR-TCR Summit Europe
DESCRIPTION:Investors in the cell therapy industry are actively looking into solid tumours\, autoimmune indications and novel engineering as the best place to allocate their money and resources. This\, along with the recent investments in Enara Bio\, ArsenalBio\, Kyverna and Artiva signifies that the field is poised to regain momentum. \nIt’s not just investments that are gaining traction. Recent approvals are changing the game\, with Iovance and Adaptimmune making strides in treating solid tumours\, Kite securing first-line treatment approval\, and donor cell therapies\, demonstrating success in putting autoimmune diseases into remission. The industry is brimming with new hope! \nThe 8th CAR-TCR Summit Europe returns to London this February as your must-attend forum to remain on the pulse of recent innovation in cell therapy. Join us to collaborate\, innovate\, and overcome the shared challenges of safety concerns\, high cost of goods\, effective tumour targeting\, and more. Let’s work together to drive success in clinical trials\, secure regulatory approvals\, and position cell therapy as the first-line treatment for oncological and non-oncological indications. \nView the agenda here: https://ter.li/6qjg6t \nSnapshot of the 50+ expert speaker faculty: \n\nBirk Vanderween\, Senior Vice President\, Global Manufacturing & Supply\, Legend Biotech \nCokey Nguyen\, President & Chief Executive Officer\, Atara Biotherapeutics \nDanielle Quarles\, Executive Director\, Clinical Operations\, Sana Biotechnology\nFranco Locatelli\, Professor\, Catholic University of Sacred Heart\, Bambion Gesu Children’s Hospital \nGwendolyn Binder\, President\, Science & Technology\, Cabaletta Bio \nMarlene Carrasco Alfonso\, Global Head Immunology Cell Therapy\, AstraZeneca \nNancy Boman\, Chief Regulatory Officer\, Adicet Bio \nRaha Jahromi\, Associate Director\, Kite\, A Gilead Company\n\nLearn more: https://ter.li/6qjg6t
URL:https://www.pharmajournalist.com/event/8th-car-tcr-summit-europe/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T052246
CREATED:20241024T112821Z
LAST-MODIFIED:20241024T112821Z
UID:39941-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:8th Antigen-Specific Immune Tolerance Drug Development Summit
DESCRIPTION:Advancing Curative Therapies for Autoimmune Diseases  \nBuilding on the success of last year’s meeting\, the 8th Antigen-Specific Immune Tolerance Summit will bring together 120+ end-to-end experts in immune tolerance for autoimmune diseases. \nAgenda highlights include: \n\nStandardizing the definition and biomarkers of tolerance to inform clinical endpoints for specific disease studies and work towards measurable milestones of efficacy\nDelving into antigen selection for complex autoimmune diseases with multiple antigen drivers to expand the wheelhouse of diseases immune tolerizing strategies can target including celiac disease\, Type 1 diabetes\, multiple sclerosis\, rheumatoid arthritis\, IBD\, and more\nAdvancing durable and efficacious ASIT therapeutics through early-stage clinical trials and beyond\n\nJoin your colleagues and thought leaders in February to take actionable insights back to your team at the industry’s only\, dedicated\, antigen-specific immune tolerance meeting. Join Eli Lilly\, AbbVie\, Pfizer\, Diamyd\, Moderna\, Toleranzia\, GRO Bio and more. \nFind out more here: https://ter.li/ujeia4
URL:https://www.pharmajournalist.com/event/8th-antigen-specific-immune-tolerance-drug-development-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250219
DTEND;VALUE=DATE:20250222
DTSTAMP:20260515T052246
CREATED:20241122T121650Z
LAST-MODIFIED:20241122T121650Z
UID:40111-1739923200-1740182399@www.pharmajournalist.com
SUMMARY:3rd Viral Vector Process Development & Manufacturing Summit
DESCRIPTION:In recent industry news\, AAV gene therapies are gaining momentum\, with groundbreaking achievements like RegenxBio’s RGX-121 trial for Hunter syndrome\, demonstrating significant improvements in neurodevelopmental skills. The global AAV therapy market\, valued at $1.5 billion in 2023\, is projected to skyrocket to $22.3 billion by 2029. However\, scaling up production remains a significant challenge\, highlighting the urgency for innovative solutions in viral vector manufacturing.​ \nThe 3rd Viral Vector Process Development & Manufacturing Summit returns to Boston to tackle these challenges head-on. Featuring over 16 expert speakers\, including Yuanli Song\, Associate Director at Sanofi\, the event offers cutting-edge insights into process optimization for viral vector production. Yuanli Song emphasized the importance of this summit\, saying\, “This summit is a vital platform that brings together experts from diverse fields to address and solve pressing challenges in viral vector process development and manufacturing. The 2025 meeting will witness valuable discussions that will help drive innovation and advance solutions for optimizing viral vector production.” \nThe agenda includes two interactive workshops and over 20 hours of insightful content designed to address upstream and downstream challenges\, improve yield\, and enhance scalability. Additionally\, attendees will benefit from 6+ hours of dedicated networking breaks\, fostering collaborations crucial for advancing this field. \nKey topics covered include: \n\nEnhancing capsid ratios and vector optimization\nInnovations in purification techniques\nSeamless tech transfer for scalability\nTackling high-dose production complexities\n\nThis summit is the ultimate opportunity for professionals from companies like Sanofi\, Kite\, Ultragenyx\, and others to stay at the forefront of viral vector manufacturing innovations. With 800+ gene therapy candidates in trials and the FDA’s evolving frameworks\, this event is essential for driving the next wave of scalable\, high–quality therapies​. \nView our agenda to find out more!
URL:https://www.pharmajournalist.com/event/3rd-viral-vector-process-development-manufacturing-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250218
DTEND;VALUE=DATE:20250220
DTSTAMP:20260515T052246
CREATED:20241127T124753Z
LAST-MODIFIED:20241127T124753Z
UID:40158-1739836800-1740009599@www.pharmajournalist.com
SUMMARY:Neuroscience Innovation Pharma Partnering Summit
DESCRIPTION:Significant breakthroughs in CNS biology\, coupled with innovative neuroscience technologies and a more supportive regulatory landscape\, have fueled increased investment and pharmaceutical interest in the CNS. \nWith AbbVie\, BMS\, and Lundbeck making major acquisitions in the last 12 months alone\, this wave of deal-making is redemption for biotech who kept the lights on and are building with greater strength than before. \nJoin the Neuroscience Innovation Pharma Partnering Summit to: \n\nConnect with a targeted critical mass of decision-makers aligned with your strategic and scientific goals.\nBuild stronger relationships with key pharma and investor contacts to emphasize your company’s competitive edge\nPosition your company at the front of scientific innovation to show where you add value\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:https://www.pharmajournalist.com/event/neuroscience-innovation-pharma-partnering-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250211
DTEND;VALUE=DATE:20250213
DTSTAMP:20260515T052246
CREATED:20250116T115239Z
LAST-MODIFIED:20250117T133524Z
UID:40306-1739232000-1739404799@www.pharmajournalist.com
SUMMARY:3rd Kinase Targeted Drug Discovery Summit
DESCRIPTION:The kinase drug discovery field is at a pivotal moment\, with recent breakthroughs from industry leaders such as Biogen\, A-Alpha Bio\, and Proxygen paving the way for exciting new approaches in targeting kinases\, particularly in targeted protein degradation. \nWith ongoing challenges including selectivity and resistance in small molecule inhibitors\, these hurdles limit the therapeutic applications and call for in-depth discussions focused on innovative future strategies for kinase targeted drugs. \nJoin 60+ peers at the 3rd Kinase Targeted Drug Discovery Summit; the premier\, target-specific conference designed to provide you with ground-breaking insights to revolutionize your kinase biology. \n\nDiscover cutting-edge developments in small molecule therapeutics\, including PROTACs\, molecular glues\, and allosteric inhibitors\nEnhance drug selectivity & tackle resistance head-on\, and identify optimal combination partners\nLead the charge in creating first-class kinase-targeted drugs that can ultimately combat disease indications and transform patient outcomes!\n\nAttendance is complimentary for drug developers & researchers (subject to T&Cs) – we’d love to welcome you to Boston in February!
URL:https://www.pharmajournalist.com/event/3rd-kinase-targeted-drug-discovery-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250129
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T052246
CREATED:20241031T113348Z
LAST-MODIFIED:20241031T113527Z
UID:40005-1738108800-1738281599@www.pharmajournalist.com
SUMMARY:9th Tumor Models San Francisco Summit 2025
DESCRIPTION:Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling better and more accessible characterization of therapeutic pathways than ever before. The challenges and opportunities in preclinical and translational research are constantly evolving\, and it has never been more critical to benchmark and share cross-industry learnings and case studies to de-risk the move to the clinic. \nReuniting 180+ Preclinical\, Translational\, Discovery\, Pharmacology\, and Biology experts to share case studies in improving target selection\, facilitating biomarker discovery\, and achieving clinical translatability\, the 9th Tumor Models San Francisco Summit is the definitive industry forum uniting the West Coast ecosystem of pharma and biotech to collaboratively advance the frontier of oncology research to the clinic.Dates: December 10-12\, 2024. \n5 Must-Attend Case Studies in 2025:\n\n\nInterrogate the translational relevance of humanized mouse models and investigate data indicating translational relevance to optimize selection criteria with Amgen\nNavigate ADC activity in immunocompetent models across syngenic and humanized models to assess clinical relevance and optimize dosing with AstraZeneca\nEvaluate T cell engagers with additional functionality and selection rationale for humanized mouse models including PBMCs\, transgenic and tox models with Zymeworks\nOptimize decision making in outsourcing or developing internal capabilities for translational studies through cost-benefit models across multiple modalities with AstraZeneca\nExplore combination dosing strategies in bispecifics and CAR-T therapies and evaluate toxicity in mouse models to optimize targeted cytokine therapies with Regeneron
URL:https://www.pharmajournalist.com/event/9th-tumor-models-san-francisco-summit-2025/
LOCATION:Grand Hyatt San Francisco\, 345 Stockton St\, San Francisco\, CA\, 94108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250128
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T052246
CREATED:20241127T123357Z
LAST-MODIFIED:20241127T123357Z
UID:40145-1738022400-1738281599@www.pharmajournalist.com
SUMMARY:3rd Ophthalmic Drug Delivery Summit
DESCRIPTION:Fresh from the reapproval of Roche/Genentech’s Susvimo\, positive readouts for sustained release implants\, and suprachoroidal delivery revolutionizing gene therapy delivery to the retina\, matching the right delivery route to the right drug has become an unavoidable topic for ophthalmology biopharma. \nThe 3rd Ophthalmic Drug Delivery Summit is the premier gathering for the industry to discuss and explore innovations and future directions for ophthalmic device and formulation development. Delve into the latest in-depth analysis of intravitreal\, subretinal\, suprachoroidal and topical delivery and explore advancements in ophthalmic pharmacology. \nWith an ever-growing market opportunity\, the industry is in an arms race to demonstrate the clinical benefits of longer lasting efficacy and less invasive drug delivery through alternative administration routes and novel ocular devices. Reuniting 60+ ophthalmic delivery innovators in sunny San Francisco\, the 3rd Ophthalmic Drug Delivery Summit is the only industry-focused meeting dedicated to translating more efficacious\, longer lasting\, and less invasive retinal delivery. Across 3 jam-packed days\, join clinical and preclinical ocular experts\, ophthalmic device engineers\, product development leaders and formulation specialists to delve a range of ocular drug-delivery systems striving to maintain drug concentrations\, reduce dosage frequency\, and overcome ocular barriers. \nThis meeting is your one-stop-shop to gather key updates on cutting-edge technologies\, ophthalmic pharmacology and to compare routes of administration capabilities to overcome anatomical barriers\, enhance bioavailability\, and improve patient outcomes such as: \n\nOptimizing sustained release formulations and release kinetics to fine-tune dosing for long-lasting retinal delivery with Genentech\, Ocular and Alcon\nEvaluating the durability and safety of delivering drugs to the retina via suprachoroidal delivery with Everads\, Genentech and Clearside\nUtilizing gene therapy transduction via sub retinal and para retinal delivery to the retina with REGENXBIO\, GelMEDIX and Ray Therapeutics\nTroubleshooting species differences and biocompatibility with ocular models to accelerate delivery translation with Genentech and Wake Forest University\nOvercoming clinical trial hurdles and achieving operational synergies to streamline development with Aviceda\, AbbVie and Regeneron\n\nDon’t miss this exclusive opportunity to meet world class ophthalmic delivery experts from the likes of Genentech\, AbbVie\, Bayer\, Clearside Biomedical\, Ocular Therapeutix\, REGENXBIO\, Regeneron\, Eyepoint Pharmaceuticals\, and more.
URL:https://www.pharmajournalist.com/event/3rd-ophthalmic-drug-delivery-summit/
LOCATION:The Clift Royal Sonesta San Francisco\, 495 Geary St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250128
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T052246
CREATED:20241031T112719Z
LAST-MODIFIED:20241031T112719Z
UID:39999-1738022400-1738281599@www.pharmajournalist.com
SUMMARY:3rd Molecular Glue Drug Development Summit
DESCRIPTION:The 3rd Molecular Glue Drug Development Summit is returning to bring together leaders across biopharma covering the depth and breadth of the molecular glue field from rational discovery to improving toxicity\, PKPD\, and late-stage development. Don’t miss out on the unparallel learning and networking opportunities on offer at this summit and join 90+ pioneering Directors\, Vice Presidents\, and Heads of Medicinal Chemistry\, Structural Biology\, and Drug Discovery to kickstart your 2025 R&D and fast-track your glues to patients in need faster. \nTo know more visit: https://ter.li/rwb5uq
URL:https://www.pharmajournalist.com/event/3rd-molecular-glue-drug-development-summit/
LOCATION:The Royal Sonesta Boston\, 40 Edwin H Land Blvd\, Cambridge\, MA\, 02142\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250128
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T052246
CREATED:20241008T142442Z
LAST-MODIFIED:20241008T144847Z
UID:39886-1738022400-1738281599@www.pharmajournalist.com
SUMMARY:6th RNAi-Based Therapeutics Summit
DESCRIPTION:RNAi Therapeutics holds more promise than ever in treating many diseases beyond the liver\, with momentum in this field growing stronger than ever. Breakthrough companies such as Argonaute RNA and Kate Therapeutics have secured funding to propel their innovative RNAi candidates and delivery platforms\, as well as pharma giants partnering with innovative biotech companies to advance RNAi candidates into the clinic. \n \nThe 6th RNAi-Based Therapeutics Summit is returning to Boston to showcase the latest delivery technologies\, data from clinically successful extra-hepatic targeting\, cutting-edge AI tools to assist payload design\, and breakthrough chemical modifications that enhance stability\, allowing for precise therapeutic delivery. \nUniting 70+ leaders of the RNAi world\, this Summit will empower experts to pioneer their RNAi candidates into clinically successful therapies. Bringing together technical and strategic experts from Novo Nordisk\, Alynlam\, Switch Therapeutics\, Aro Biotherapeutics\, Novartis\, Comanche Biopharma\, and more\, this meeting is a unique gathering of RNAi’s sharpest minds\, dedicated to progressing the next wave of RNAi therapeutics to improve healthcare for patients in need. \nWant to learn more? Download our official brochure here: https://ter.li/00r79n
URL:https://www.pharmajournalist.com/event/6th-rnai-based-therapeutics-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250128
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T052246
CREATED:20241008T141023Z
LAST-MODIFIED:20241008T141023Z
UID:39875-1738022400-1738281599@www.pharmajournalist.com
SUMMARY:4th mRNA-Based Therapeutics Summit Europe
DESCRIPTION:The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt\, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets\, never-before-seen pre-clinical and clinical data\, and demonstrating key routes to commercial success for mRNA therapy and vaccine R&D pipelines. \nWhether you’re entering the mRNA arena for the first time or a well-seasoned mRNA veteran\, with two dedicated tracks of content spanning discovery through commercialisation\, this forum will equip you with the know-how and connections to make rapid advances in your work with partnering and collaborative networking opportunities spread throughout. \nAssembling 200+ mRNA enthusiasts from across Europe\, Asia and the globe\, this is your one-stop-shop to gain unparalleled overview of cutting-edge R&D innovations\, whilst diving deep into end-to-end development strategy to revolutionise the next wave of mRNA medicines towards clinical reality. \nDownload the event guide for full details: https://ter.li/qd1z5z
URL:https://www.pharmajournalist.com/event/4th-mrna-based-therapeutics-summit-europe/
LOCATION:Sheraton Frankfurt Airport Hotel & Conference Center\, Hugo-Eckener-Ring 15/Terminal 1\, Frankfurt am Main\, 60549\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR